| $337M | ||
| $259M | ||
| $100M | ||
| $79M | ||
| $60M | ||
| $58M |
Buys | $4,955,728 | 1 | 20 |
Sells | $2,586,523 | 4 | 80 |
| Chambers Michael Andrew | director | 1 | $4.96M | 0 | $0 | $4.96M |
| Boor Kathryn Jean | director | 0 | $0 | 1 | $205,400 | $-205,400 |
| Nicaise Claude | director | 0 | $0 | 1 | $248,203 | $-248,203 |
| Estepan Ian Michael | Chief Financial Officer | 0 | $0 | 1 | $822,100 | $-822,100 |
| Wigzell Hans Lennart Rudolf | director | 0 | $0 | 1 | $1.31M | $-1.31M |
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
Over the last 12 months, insiders at Sarepta Therapeutics, Inc. have bought $4.96M and sold $2.59M worth of Sarepta Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Sarepta Therapeutics, Inc. have bought $6.22M and sold $6.04M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Chambers Michael Andrew (director) — $4.96M.
The last purchase of 37,038 shares for transaction amount of $4.96M was made by Chambers Michael Andrew (director) on 2024‑08‑16.
| 2025-03-12 | Sale | Nicaise Claude | director | 2,491 0.0026% | $99.64 | $248,203 | -60.28% | |
| 2024-12-12 | Sale | Wigzell Hans Lennart Rudolf | director | 10,500 0.011% | $124.84 | $1.31M | -48.73% | |
| 2024-12-05 | Sale | Boor Kathryn Jean | director | 1,636 0.0017% | $125.55 | $205,400 | -42.71% | |
| 2024-08-30 | Sale | Estepan Ian Michael | Chief Financial Officer | 5,985 0.0063% | $137.36 | $822,100 | -19.22% | |
| 2024-08-16 | Chambers Michael Andrew | director | 37,038 0.0404% | $133.80 | $4.96M | -16.00% | ||
| 2024-06-25 | Sale | Arif Bilal | Chief Tech Ops Officer | 3,898 0.0043% | $163.23 | $636,271 | -24.72% | |
| 2024-06-25 | Sale | Brown Ryan Edward | EVP, General Counsel | 38,957 0.0421% | $161.61 | $6.3M | -24.72% | |
| 2024-06-24 | Sale | Arif Bilal | Chief Tech Ops Officer | 7,859 0.0083% | $163.08 | $1.28M | -27.32% | |
| 2024-05-02 | Sale | Murray Dallan | Chief Customer Officer | 3,635 0.0041% | $140.00 | $508,900 | -5.14% | |
| 2024-03-11 | Sale | Boor Kathryn Jean | director | 761 0.0008% | $122.93 | $93,550 | +3.09% | |
| 2024-03-08 | Sale | Wigzell Hans Lennart Rudolf | director | 15,000 0.0159% | $123.25 | $1.85M | +0.78% | |
| 2024-03-05 | Sale | Mayo Stephen | director | 3,135 0.0033% | $122.96 | $385,480 | +2.03% | |
| 2024-03-01 | Sale | Estepan Ian Michael | Chief Financial Officer | 1,200 0.0013% | $128.30 | $153,960 | -2.59% | |
| 2024-03-01 | Sale | Brown Ryan Edward | EVP, General Counsel | 2,000 0.0021% | $125.34 | $250,680 | -2.59% | |
| 2024-03-01 | Sale | Arif Bilal | Chief Tech Ops Officer | 2,000 0.0021% | $128.84 | $257,676 | -2.59% | |
| 2023-11-03 | INGRAM DOUGLAS S | President & CEO | 25,225 0.0275% | $79.36 | $2M | +60.46% | ||
| 2023-11-03 | Barry Richard | director | 50,000 0.0542% | $78.81 | $3.94M | +60.46% | ||
| 2023-08-14 | Chambers Michael Andrew | director | 9,979 0.0104% | $109.47 | $1.09M | +7.99% | ||
| 2023-08-11 | Chambers Michael Andrew | director | 23,686 0.0254% | $108.05 | $2.56M | +12.24% | ||
| 2023-08-10 | Chambers Michael Andrew | director | 34,867 0.0374% | $106.15 | $3.7M | +14.36% |
| Chambers Michael Andrew | director | 284034 0.289% | $5.46M | 5 | 0 | +11.57% |
| Estepan Ian Michael | Chief Financial Officer | 33946 0.0345% | $652,781.58 | 0 | 2 | |
| Nicaise Claude | director | 27812 0.0283% | $534,824.76 | 0 | 1 | |
| Wigzell Hans Lennart Rudolf | director | 22840 0.0232% | $439,213.20 | 0 | 10 | |
| Boor Kathryn Jean | director | 5880 0.006% | $113,072.40 | 0 | 2 | |
| HAYWOOD GEORGE WEAVER | 8213717 8.3577% | $157.95M | 16 | 0 | <0.0001% | |
| EASTBOURNE CAPITAL MANAGEMENT LLC/CA | 10 percent owner | 5659211 5.7584% | $108.83M | 0 | 2 | |
| kole Ryszard | Senior Vice President | 1841494 1.8738% | $35.41M | 0 | 4 | |
| INGRAM DOUGLAS S | President & CEO | 390307 0.3971% | $7.51M | 7 | 0 | +25.87% |
| Hudson Leslie | Former CEO | 384559 0.3913% | $7.4M | 0 | 12 | |
| Barry Richard | director | 140000 0.1425% | $2.69M | 7 | 3 | +30.38% |
| BEHRENS M KATHLEEN | director | 130517 0.1328% | $2.51M | 6 | 2 | +42.52% |
| BOYLE J DAVID II | CEO | 70282 0.0715% | $1.35M | 2 | 0 | +60.55% |
| Rodino-Klapac Louise | Head of R&D, CSO | 65678 0.0668% | $1.26M | 1 | 0 | +1.95% |
| Kaye Edward M. MD | director | 52471 0.0534% | $1.01M | 1 | 4 | |
| Price Ben Gil | director | 42830 0.0436% | $823,620.90 | 10 | 0 | +41.98% |
| CHASE ANTHONY R | director | 41744 0.0425% | $802,737.12 | 9 | 4 | +41.16% |
| Howton David T | EVP, General Counsel | 31871 0.0324% | $612,879.33 | 0 | 8 | |
| Mahatme Sandesh | EVP, CFO & CBO | 30179 0.0307% | $580,342.17 | 1 | 7 | |
| Christopher Nishan Garabedian | President and CEO | 29552 0.0301% | $568,284.96 | 3 | 0 | <0.0001% |
| Ruff Shamim | SVP, Regulatory Affairs & Qual | 27045 0.0275% | $520,075.35 | 0 | 5 | |
| Murray Dallan | Chief Customer Officer | 18125 0.0184% | $348,543.75 | 0 | 1 | |
| Arif Bilal | Chief Tech Ops Officer | 17363 0.0177% | $333,890.49 | 0 | 3 | |
| Brown Ryan Edward | EVP, General Counsel | 17129 0.0174% | $329,390.67 | 0 | 2 | |
| Aphale Jayant | VP, Technical Operations | 11490 0.0117% | $220,952.70 | 0 | 2 | |
| Bratica Joseph | Principal Financial Officer | 8140 0.0083% | $156,532.20 | 0 | 3 | |
| BONNEY MICHAEL W | director | 7051 0.0072% | $135,590.73 | 1 | 0 | +39.82% |
| Mayo Stephen | director | 6621 0.0067% | $127,321.83 | 0 | 2 | |
| HODGMAN JOHN | director | 4333 0.0044% | $83,323.59 | 0 | 1 | |
| Cumbo Alexander | EVP, Chief Commercial Officer | 1867 0.0019% | $35,902.41 | 0 | 4 |
$193,151,375 | 134 | 8.18% | $1.92B | |
$21,345,882 | 83 | 94.45% | $1.87B | |
$54,590,806 | 65 | 21.84% | $1.8B | |
Sarepta Therapeutics, Inc. (SRPT) | $42,463,802 | 57 | 17.85% | $1.89B |
$1,376,668 | 53 | 18.46% | $2B | |
$148,770,544 | 34 | 80.63% | $1.52B | |
$309,951,506 | 30 | 32.56% | $1.62B | |
$1,295,059 | 29 | 102.78% | $1.55B | |
$150,253,463 | 26 | -52.83% | $2.02B | |
$137,027,226 | 13 | 28.32% | $1.9B | |
$1,248,715 | 10 | 5.66% | $2.09B | |
$45,445,266 | 9 | -24.96% | $1.98B | |
$32,575,266 | 8 | 37.03% | $1.74B | |
$107,098,946 | 7 | 1.61% | $1.55B | |
$25,073,947 | 7 | -5.99% | $1.99B | |
$21,792,890 | 6 | 75.72% | $1.76B | |
$24,000,085 | 4 | 33.26% | $2B | |
$7,600,000 | 1 | -4.05% | $1.97B | |
$5,000,000 | 1 | -22.84% | $1.75B |
| Increased Positions | 225 | +39.89% | 11M | +11.81% |
| Decreased Positions | 250 | -44.33% | 11M | -12.56% |
| New Positions | 72 | New | 3M | New |
| Sold Out Positions | 101 | Sold Out | 3M | Sold Out |
| Total Postitions | 539 | -4.43% | 89M | -0.76% |
| Blackrock, Inc. | $629,185.00 | 10.11% | 9.91M | -1M | -11.48% | 2025-03-31 |
| Vanguard Group Inc | $577,017.00 | 9.27% | 9.09M | +117,904 | +1.31% | 2024-12-31 |
| Capital International Investors | $552,355.00 | 8.88% | 8.7M | +2M | +38.95% | 2024-12-31 |
| Janus Henderson Group Plc | $274,892.00 | 4.42% | 4.33M | -30,188 | -0.69% | 2024-12-31 |
| State Street Corp | $258,477.00 | 4.15% | 4.07M | -200,902 | -4.7% | 2024-12-31 |
| Farallon Capital Management Llc | $181,963.00 | 2.92% | 2.87M | +285,100 | +11.05% | 2024-12-31 |
| Avoro Capital Advisors Llc | $162,303.00 | 2.61% | 2.56M | 0 | 0% | 2024-12-31 |
| Wellington Management Group Llp | $131,388.00 | 2.11% | 2.07M | -657,842 | -24.13% | 2024-12-31 |
| Jpmorgan Chase & Co | $128,329.00 | 2.06% | 2.02M | -178,279 | -8.11% | 2024-12-31 |
| T. Rowe Price Investment Management, Inc. | $124,263.00 | 2% | 1.96M | +10,343 | +0.53% | 2024-12-31 |